The DOI matches its Crossref record.
A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures — A randomized, active comparator, double-blind study
Open accessAbstract
BACKGROUND: Eldecalcitol is an analog of 1,25-dihydroxyvitamin D(3) that improves bone mineral density; however, the effect of eldecalcitol on the risk of fractures is unclear. The objective of this study is to examine whether eldecalcitol is superior to alfacalcidol in preventing osteoporotic fractures. This trial is registered with ClinicalTrials.gov, number NCT00144456. METHODS AND RESULTS: This 3 year randomized, double-blind, active comparator, superiority trial tested the efficacy of daily oral 0.75 μg eldecalcitol versus 1.0 μg alfacalcidol for prevention of osteoporotic fractures. 1054 osteoporotic patients 46 to 92 years old were randomly assigned 1:1 to receive eldecalcitol (n=528) or alfacalcidol (n=526). Patients were stratified by study site and serum 25-hydroxyvitamin D level. Patients with low serum 25-hydroxyvitamin D levels (<50 nmol/L) were supplemented with 400 IU/day vitamin D(3). Primary end point was incident vertebral fractures. Secondary end points included any non-vertebral fractures and change in bone mineral density and bone turnover markers. Compared with the alfacalcidol group, the incidence of vertebral fractures was lower in eldecalcitol group after 36 months of treatment (13.4 vs. 17.5%; hazard ratio, 0.74; predefined 90% confidence interval [CI], 0.56-0.97). Eldecalcitol reduced turnover markers and increased bone mineral density more strongly than alfacalcidol. Eldecalcitol reduced the incidence of three major non-vertebral fractures, which was due to a marked reduction in wrist fractures by a post-hoc analysis (1.1 vs. 3.6%; hazard ratio, 0.29; 95% CI, 0.11-0.77). Among the adverse events, the incidence of increase in serum and urinary calcium was higher in the eldecalcitol group, without any difference in glomerular filtration rate between the two groups. CONCLUSIONS: Eldecalcitol is more efficacious than alfacalcidol in preventing vertebral and wrist fractures in osteoporotic patients with vitamin D sufficiency, with a safety profile similar to alfacalcidol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary
Orimo, H., Nakamura, T., Hosoi, T., Iki, M., Uenishi, K., Endo, N., Ohta, H., Shiraki, M., Sugimoto, T., Suzuki, T., et al. (2012) · Archives of Osteoporosis · doi:10.1007/s11657-012-0109-9 · Cited by 358
Self-citationVitamin D, calcium homeostasis and aging
Veldurthy, V., Wei, R., Oz, L., Dhawan, P., Jeon, Y. H., & Christakos, S. (2016) · Bone Research · doi:10.1038/boneres.2016.41 · Cited by 356
Metadata
- Authors
- Matsumoto, T., Ito, M., Hayashi, Y., Hirota, T., Tanigawara, Y., Sone, T., Fukunaga, M., Shiraki, M., & Nakamura, T.
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 49
- Issue
- 4
- Pages
- 605-612
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W1999438656
- Cited by
- 189
- References
- 0
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures — A randomized, active comparator, double-blind study. https://app.cochat.ai/papers/10.1016/j.bone.2011.07.011
- The paper
- Matsumoto, T., Ito, M., Hayashi, Y., Hirota, T., Tanigawara, Y., Sone, T., Fukunaga, M., Shiraki, M., & Nakamura, T. (2011). A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures — A randomized, active comparator, double-blind study. Bone. https://doi.org/10.1016/j.bone.2011.07.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.